Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest
出版年份 2015 全文链接
标题
Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest
作者
关键词
-
出版物
CANCER SCIENCE
Volume 106, Issue 3, Pages 287-293
出版商
Wiley
发表日期
2015-01-10
DOI
10.1111/cas.12605
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Identification and Characterization of Small Molecules That Inhibit Nonsense-Mediated RNA Decay and Suppress Nonsense p53 Mutations
- (2014) L. Martin et al. CANCER RESEARCH
- Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy
- (2014) Lewis R. Silverman et al. HEMATOLOGICAL ONCOLOGY
- Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes
- (2013) Rami S. Komrokji et al. BRITISH JOURNAL OF HAEMATOLOGY
- Depletion of RNA-binding protein RBM8A (Y14) causes cell cycle deficiency and apoptosis in human cells
- (2013) Yasuhito Ishigaki et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Inhibition of Nonsense-Mediated RNA Decay Activates Autophagy
- (2013) J. Wengrod et al. MOLECULAR AND CELLULAR BIOLOGY
- Revised International Prognostic Scoring System for Myelodysplastic Syndromes
- (2012) P. L. Greenberg et al. BLOOD
- ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress
- (2012) C. M. Chapman et al. CLINICAL CANCER RESEARCH
- Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines
- (2012) Takayuki Tsujioka et al. EXPERIMENTAL HEMATOLOGY
- Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na
- (2012) Matthew J. Olnes et al. LEUKEMIA RESEARCH
- Targeting cyclin D1 for high risk myelodysplastic syndromes
- (2012) Suneel D. Mundle LEUKEMIA RESEARCH
- New therapeutics for myelodysplastic syndromes
- (2012) Alan F. List LEUKEMIA RESEARCH
- The potential role of Aurora kinase inhibitors in haematological malignancies
- (2011) Sherif S. Farag BRITISH JOURNAL OF HAEMATOLOGY
- Effect of ON 01910.Na, an Anticancer Mitotic Inhibitor, on Cell-Cycle Progression Correlates with RanGAP1 Hyperphosphorylation
- (2011) I. A. Oussenko et al. CANCER RESEARCH
- Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na
- (2011) Mahesh Seetharam et al. LEUKEMIA RESEARCH
- Failure of Hypomethylating Agent–Based Therapy in Myelodysplastic Syndromes
- (2011) Tapan M. Kadia et al. SEMINARS IN ONCOLOGY
- Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis
- (2010) A Matsuoka et al. LEUKEMIA
- Nonsense-Mediated RNA Decay Regulation by Cellular Stress: Implications for Tumorigenesis
- (2010) L. B. Gardner MOLECULAR CANCER RESEARCH
- Therapy with azanucleosides for myelodysplastic syndromes
- (2010) Alfonso Quintás-Cardama et al. Nature Reviews Clinical Oncology
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Many are called MDS cell lines: One is chosen
- (2009) Hans G. Drexler et al. LEUKEMIA RESEARCH
- Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells
- (2009) A Prasad et al. ONCOGENE
- Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology
- (2009) P. Schoffski ONCOLOGIST
- Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors
- (2008) Antonio Jimeno et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started